person · Reporting owner

Legault Pierre

Disclosed activity across 6 companies

Tapewire entity: 67394
SEC CIK: 0001391045

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adynxx, Inc.ADYX · Entity 155807	Director	May 03, 2019	May 07, 2019
BICYCLE THERAPEUTICS PLCBCYC · Entity 5993	Director	January 02, 2025	January 06, 2025
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director	February 04, 2026	February 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adynxx, Inc.

Report date May 03, 2019 · Filed May 07, 2019

This filing explicitly reported no securities owned.

BICYCLE THERAPEUTICS PLC

Report date January 02, 2025 · Filed January 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	46,000	Reported balance After 2025-01-02 transaction · row 1 1 source row Row 1 · 2025-01-02 · Grant · Acquired 12,500 · Balance 46,000 F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2: Each RSU represents a contingent right to receive one ordinary share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-01-02	Direct	25,000	Reported balance After 2025-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-02 · Grant · Acquired 25,000 · Balance 25,000 F3: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.

F2: Each RSU represents a contingent right to receive one ordinary share.

F3: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.

Syndax Pharmaceuticals Inc

Report date February 04, 2026 · Filed February 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	114,000	Reported balance After 2026-02-04 transaction · row 1 1 source row Row 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 114,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARMO BioSciences, Inc.

Report date March 26, 2018 · Filed June 22, 2018

Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2028-03-25	Direct	0	Reported balance After 2018-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.73 · Expires 2027-05-31	Direct	0	Reported balance After 2018-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-22 · Disposition to issuer · Disposed 55,765 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which provided for vesting in forty-eight equal monthly installments following April 18, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F4: This option, which provided for vesting in forty-eight equal monthly installments following April 18, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 03, 2016

Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.83 · Expires 2023-11-17	Direct	Reported balance After 2016-11-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-11-01 · Disposition to issuer · Disposed 6,111 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.93 · Expires 2023-12-31	Direct	Reported balance After 2016-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-01 · Disposition to issuer · Disposed 535 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2025-07-08	Direct	Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-01 · Disposition to issuer · Disposed 15,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.91 · Expires 2026-01-12	Direct	Reported balance After 2016-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-01 · Disposition to issuer · Disposed 17,778 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.19 · Expires 2025-01-01	Direct	Reported balance After 2016-11-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-11-01 · Disposition to issuer · Disposed 17,695 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time")

F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"),

F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor.

F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Urovant Sciences Ltd.

Report date March 29, 2021 · Filed March 31, 2021

Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-03-29 · Disposition to issuer · Disposed 12,480 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-03-29 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.53 · Expires 2028-06-09	Direct	Reported balance After 2021-03-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-29 · Disposition to issuer · Disposed 13,350 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2028-11-21	Direct	Reported balance After 2021-03-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-29 · Disposition to issuer · Disposed 36,650 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2029-07-09	Direct	Reported balance After 2021-03-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-03-29 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2030-07-21	Direct	Reported balance After 2021-03-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-03-29 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 05, 2021 Filed Apr 7, 2021 19:22 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	162	$8.83	$1,430.46	Disclosure SEC source: 0001209191-21-025990 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.38618 to GBP 1.00 as of April 5, 2021. Read SEC document
March 31, 2021 Filed Apr 2, 2021 16:44 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0001209191-21-024639 · doc4.xml · derivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,312 Underlying: Ordinary Shares · 10,000 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.37827 to GBP 1.00 as of March 31, 2021. F3 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
March 31, 2021 Filed Apr 2, 2021 16:44 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	10,000	$30.00	$300,000.00	Disclosure SEC source: 0001209191-21-024639 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document
March 31, 2021 Filed Apr 2, 2021 16:44 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	10,000	$8.78	$87,800.00	Disclosure SEC source: 0001209191-21-024639 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.37827 to GBP 1.00 as of March 31, 2021. Read SEC document
March 29, 2021 Filed Mar 31, 2021 12:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0000899243-21-014108 · doc4.xml · derivative · entry 6 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,000 shares Expires 2030-07-21 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 12:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0000899243-21-014108 · doc4.xml · derivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 25,000 shares Expires 2029-07-09 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 12:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	36,650	$0.00 Strike: $8.01	$0.00	Disclosure SEC source: 0000899243-21-014108 · doc4.xml · derivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 36,650 shares Expires 2028-11-21 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 12:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerStock Option (Right to Buy) · Derivative	13,350	$0.00 Strike: $7.53	$0.00	Disclosure SEC source: 0000899243-21-014108 · doc4.xml · derivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 13,350 shares Expires 2028-06-09 F3 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 12:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerCommon Shares	9,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-014108 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 29, 2021 Filed Mar 31, 2021 12:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	Disposition to issuerCommon Shares	12,480	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-014108 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document
March 17, 2021 Filed Mar 19, 2021 16:48 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	7,784	$0.00 Strike: $8.85	$0.00	Disclosure SEC source: 0001209191-21-022103 · doc4.xml · derivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,312 Underlying: Ordinary Shares · 7,784 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3898 to GBP 1.00 as of March 17, 2021. F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
March 17, 2021 Filed Mar 19, 2021 16:48 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	7,784	$29.00	$225,736.00	Disclosure SEC source: 0001209191-21-022103 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
March 17, 2021 Filed Mar 19, 2021 16:48 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	7,784	$8.85	$68,888.40	Disclosure SEC source: 0001209191-21-022103 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.3898 to GBP 1.00 as of March 17, 2021. Read SEC document
March 12, 2021 Filed Mar 16, 2021 19:42 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	2,216	$0.00 Strike: $8.86	$0.00	Disclosure SEC source: 0001209191-21-021154 · doc4.xml · derivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,096 Underlying: Ordinary Shares · 2,216 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39126 to GBP 1.00 as of March 12, 2021. F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
March 12, 2021 Filed Mar 16, 2021 19:42 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	2,216	$29.00	$64,264.00	Disclosure SEC source: 0001209191-21-021154 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
March 12, 2021 Filed Mar 16, 2021 19:42 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	2,216	$8.86	$19,633.76	Disclosure SEC source: 0001209191-21-021154 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.39126 to GBP 1.00 as of March 12, 2021. Read SEC document
February 03, 2021 Filed Feb 5, 2021 16:18 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0001562180-21-000928 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
January 04, 2021 Filed Jan 5, 2021 17:44 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	38,000	$0.00 Strike: $17.95	$0.00	Disclosure SEC source: 0001209191-21-001407 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Ordinary Shares · 38,000 shares Expires 2031-01-04 Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:33 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0001209191-20-043484 · doc4.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-07-21 F2 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:33 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantCommon Shares	9,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-043484 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,480 F1 · shares: The Restricted Stock Units shall vest on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
February 12, 2020 Filed Feb 14, 2020 16:35 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $9.47	$0.00	Disclosure SEC source: 0001562180-20-001230 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Read SEC document
January 10, 2020 Filed Jan 14, 2020 16:06 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantCommon Shares	12,480	$0.00	$0.00	Disclosure SEC source: 0001209191-20-003283 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,480 F1 · shares: The Restricted Stock Units shall vest on January 10, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
January 02, 2020 Filed Jan 6, 2020 17:16 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	32,000	$0.00 Strike: $9.82	$0.00	Disclosure SEC source: 0001209191-20-002019 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Ordinary Shares · 32,000 shares Expires 2030-01-02 Read SEC document
July 09, 2019 Filed Jul 11, 2019 13:15 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0001209191-19-041790 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2029-07-09 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document
June 28, 2019 Filed Apr 27, 2020 16:49 UTC Amendment	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (Right to Buy) · Derivative	116,827	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001209191-20-025817 · doc4a.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,827 Underlying: Ordinary Shares · 116,827 shares Expires 2029-06-28 F1 · date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. F2 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. F1 · derivative.expiration_date: The original Form 4 inadvertently listed the incorrect date of earliest transaction, transaction date and expiration date. This Form 4 amendment is being filed to accurately reflect the appropriates dates. Read SEC document
June 10, 2019 Filed Jun 12, 2019 09:00 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $7.88	$0.00	Disclosure SEC source: 0001562180-19-003490 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Read SEC document
May 28, 2019 Filed May 30, 2019 21:25 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (Right to Buy) · Derivative	116,827	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001104659-19-032913 · a4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,827 Underlying: Ordinary Shares · 116,827 shares Expires 2029-05-28 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document
November 21, 2018 Filed Nov 26, 2018 20:38 UTC	Urovant Sciences Ltd. UROV · Entity 140739	GrantStock Option (Right to Buy) · Derivative	36,650	$0.00 Strike: $8.01	$0.00	Disclosure SEC source: 0000899243-18-029669 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,650 Underlying: Common Shares · 36,650 shares Expires 2028-11-21 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on November 9, 2019, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document
June 22, 2018 Filed Jun 22, 2018 17:15 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	Disposition to issuerStock Option (right to buy) · Derivative	55,765	$43.27 Strike: $6.73	$2,412,711.76	Disclosure SEC source: 0000899243-18-017720 · doc4.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,765 shares Expires 2027-05-31 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4 · derivative.exercise_date: This option, which provided for vesting in forty-eight equal monthly installments following April 18, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
June 22, 2018 Filed Jun 22, 2018 17:15 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	Disposition to issuerStock Option (right to buy) · Derivative	18,000	$10.03 Strike: $39.97	$180,540.00	Disclosure SEC source: 0000899243-18-017720 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-03-25 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document
May 23, 2018 Filed May 25, 2018 08:59 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $8.93	$0.00	Disclosure SEC source: 0001562180-18-002681 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-05-23 Read SEC document
March 26, 2018 Filed Mar 28, 2018 16:56 UTC	ARMO BioSciences, Inc. ARMO · Entity 12201	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $39.97	$0.00	Disclosure SEC source: 0000899243-18-008732 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-03-25 F1 · derivative.exercise_date: 1/36th of the shares of common stock subject to the option vest on the last day of the calendar month in which the option was granted, and 1/36th of the shares subject to the option vest on the last day of the 35 calendar months immediately thereafter. Read SEC document
February 08, 2018 Filed Feb 12, 2018 16:01 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $9.63	$0.00	Disclosure SEC source: 0001562180-18-000722 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document
May 17, 2017 Filed May 19, 2017 11:26 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $13.58	$0.00	Disclosure SEC source: 0001562180-17-002008 · primarydocument.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document
May 17, 2017 Filed May 19, 2017 11:26 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $13.58	$0.00	Disclosure SEC source: 0001562180-17-002008 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Read SEC document
January 04, 2017 Filed Jan 5, 2017 17:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $7.08	$0.00	Disclosure SEC source: 0001562180-17-000193 · primarydocument.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,695	Not disclosed Strike: $8.19	Not disclosed	Disclosure SEC source: 0001209191-16-148106 · doc4.xml · derivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,695 shares Expires 2025-01-01 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,778	Not disclosed Strike: $7.91	Not disclosed	Disclosure SEC source: 0001209191-16-148106 · doc4.xml · derivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,778 shares Expires 2026-01-12 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,500	Not disclosed Strike: $16.52	Not disclosed	Disclosure SEC source: 0001209191-16-148106 · doc4.xml · derivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires 2025-07-08 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	535	Not disclosed Strike: $42.93	Not disclosed	Disclosure SEC source: 0001209191-16-148106 · doc4.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 535 shares Expires 2023-12-31 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document
November 01, 2016 Filed Nov 3, 2016 14:30 UTC	Tobira Therapeutics, Inc. TBRA · Entity 181299	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	6,111	Not disclosed Strike: $43.83	Not disclosed	Disclosure SEC source: 0001209191-16-148106 · doc4.xml · derivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,111 shares Expires 2023-11-17 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · price: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · price: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2 · derivative.exercise_date: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3 · derivative.exercise_date: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4 · derivative.exercise_date: The Shares subject to this option were fully vested immediately prior to the Effective Time. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.